Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

New Horizon Health  / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/new-horizon-health-limited" target="_blank" data-smartkarma-citation="entities:31039:1" rel="noopener">New Horizon Health (NHH HK)</a>  is the pioneer in China’s colorectal cancer screening market. The company currently has two proprietary cancer screening products, ColoClear and Pupu Tube that are developed for screening colorectal cancer. Colorectal cancer screening tests have huge market potential in China given China has the highest colorectal cancer incidence in the world.The company’s proprietary, non-invasive, multi-target, FIT-DNA test is the first and only molecular screening test that is approved in China by the NMPA. ColoClear targets a high-risk colorectal cancer population of 120m in China.The company has set the terms for its IPO, where it plans to raise net proceeds of US$176-208m (approx. HK$1.4-1.6bn) through the issuance of 76.6m shares at an indicative IPO price range of HK$22.66-26.66 per share.

New Horizon Health (NHH HK)  is the pioneer in China’s colorectal cancer screening market. The company currently has two proprietary cancer screening products, ColoClear and Pupu Tube that are developed for screening colorectal cancer. Colorectal cancer screening tests have huge market potential in China given China has the highest colorectal cancer incidence in the world.The company’s proprietary, non-invasive, multi-target, FIT-DNA test is the first and only molecular screening test that is approved in China by the NMPA. ColoClear targets a high-risk colorectal cancer population of 120m in China.The company has set the terms for its IPO, where it plans to raise net proceeds of US$176-208m (approx. HK$1.4-1.6bn) through the issuance of 76.6m shares at an indicative IPO price range of HK$22.66-26.66 per share.

New Horizon Health IPO Valuation: Healthy Valuation

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

<a href="https://www.smartkarma.com/entities/new-horizon-health-limited" target="_blank" data-smartkarma-citation="entities:31039:1" rel="noopener">New Horizon Health (NHH HK)</a> has announced terms of its US$263MM IPO with a pre-money valuation of US$960 million to US$1.17 billion. The updated filings show a strong recovery in volumes from COVID-19 disruptions. We think the valuation is reasonable using undemanding assumptions and would participate in the offering.

New Horizon Health (NHH HK) has announced terms of its US$263MM IPO with a pre-money valuation of US$960 million to US$1.17 billion. The updated filings show a strong recovery in volumes from COVID-19 disruptions. We think the valuation is reasonable using undemanding assumptions and would participate in the offering. 

New Horizon IPO: Only Undemanding Assumptions Needed

Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

Edison Investment Research is terminating coverage on Epigenomics (ECX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Edison Investment Research is terminating coverage on Epigenomics (ECX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Epigenomics AG (ECX GR)

New Horizon Health IPO Valuation: Healthy Valuation

The company has set the terms for its IPO, where it plans to raise net proceeds of US$176-208m (approx. HK$1.4-1.6bn) through the issuance of 76.6m...

Shifara Samsudeen, ACMA, CGMA

New Horizon IPO: Only Undemanding Assumptions Needed

We think the proposed valuation of New Horizon Health's (NHH HK) IPO is reasonable using undemanding assumptions and would participate in the...

Kemp Dolliver, CFA

Termination of coverage

Edison Investment Research is terminating coverage on Epigenomics (ECX). Please note you should no longer rely on any previous research or...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)